In a region marked by challenges such as armed violence, insecurity, human mobility, and the impacts of climate change, representatives from governments, civil society, and international organizations gathered this week in Montevideo
More
Elite law firms are being forced to rethink their recruitment strategies as straightforward salary increases no longer persuade the most profitable partners to switch firms. Legal recruiters say that when a partner
More
In one of the most talked-about lateral moves in recent memory, Bill Savitt has departed Wachtell to join Gibson Dunn, bringing six colleagues with him. Savitt was not merely a senior partner
More
Next has upgraded its full-year profit guidance for the third time in 2026, offering fresh hope that UK consumers remain willing to spend despite ongoing household budget pressures. The clothing and homeware
More
Wall Street indices climbed to record highs as investor sentiment improved significantly following signals that the Strait of Hormuz could reopen to commercial shipping traffic. The Strait of Hormuz is one of
More
Europe is grappling with a drought so severe that governments are resorting to underwater explosions and emergency military deployments to protect critical energy infrastructure and trade routes. Romania recently shut down its
More
A dividend yield of 9.35% from a FTSE-listed company has caught the attention of income-focused investors seeking strong returns in the current market. Such an elevated yield is rare in today’s investment
More
Beazley (BEZ), the FTSE 100 specialty insurer, has reported a dramatic fall in profits for the first half of 2026, blaming war and escalating global risks for the sharp decline. The London-listed
More
Pfizer has announced an additional $2.5 billion in planned cost savings, extending its sweeping cutback programme through 2029 and bringing its total reduction target to $9.7 billion. The New York-based pharmaceutical giant
More
Merck (MRK) is pushing into one of the pharmaceutical industry’s most closely watched therapeutic categories with its newly developed oral cholesterol treatment, Lipfendra. The drug belongs to the PCSK9 inhibitor class, a
More